SG11202002268XA - Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder - Google Patents
Therapy monitoring under treatment with an anti-adrenomedullin (adm) binderInfo
- Publication number
- SG11202002268XA SG11202002268XA SG11202002268XA SG11202002268XA SG11202002268XA SG 11202002268X A SG11202002268X A SG 11202002268XA SG 11202002268X A SG11202002268X A SG 11202002268XA SG 11202002268X A SG11202002268X A SG 11202002268XA SG 11202002268X A SG11202002268X A SG 11202002268XA
- Authority
- SG
- Singapore
- Prior art keywords
- adrenomedullin
- adm
- binder
- under treatment
- monitoring under
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physiology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17197177 | 2017-10-18 | ||
PCT/EP2018/078647 WO2019077082A1 (en) | 2017-10-18 | 2018-10-18 | Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202002268XA true SG11202002268XA (en) | 2020-04-29 |
Family
ID=60301753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202002268XA SG11202002268XA (en) | 2017-10-18 | 2018-10-18 | Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220268761A1 (en) |
EP (1) | EP3698134A1 (en) |
JP (1) | JP2021500548A (en) |
CN (1) | CN111480076A (en) |
AU (1) | AU2018350861A1 (en) |
BR (1) | BR112020005682A2 (en) |
CA (1) | CA3079112A1 (en) |
MX (1) | MX2020004072A (en) |
SG (1) | SG11202002268XA (en) |
WO (1) | WO2019077082A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7291688B2 (en) * | 2017-09-13 | 2023-06-15 | ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | Adrenomezrin precursors as an index for renal replacement therapy in critically ill patients. |
EP4021571A1 (en) * | 2019-08-30 | 2022-07-06 | 4TEEN4 Pharmaceuticals GmbH | Therapy guidance and/or therapy monitoring for treatment of shock |
EP3871689A1 (en) * | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
EP4110811A1 (en) * | 2020-02-27 | 2023-01-04 | AdrenoMed AG | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
EP4111204A1 (en) * | 2020-02-27 | 2023-01-04 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock |
WO2022234111A1 (en) | 2021-05-07 | 2022-11-10 | Sphingotec Gmbh | Mature adrenomedullin for therapy stratification of corticosteroids in critically ill patients |
WO2023175035A1 (en) * | 2022-03-15 | 2023-09-21 | Adrenomed Ag | Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DK0463151T3 (en) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Generation of xenogenic antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
ATE185601T1 (en) | 1990-07-10 | 1999-10-15 | Cambridge Antibody Tech | METHOD FOR PRODUCING SPECIFIC BONDING PAIRS |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
JPH07503132A (en) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル,インコーポレイティド | Transgenic non-human animals capable of producing xenoantibodies |
JP2774769B2 (en) | 1993-04-26 | 1998-07-09 | 賢治 寒川 | Adrenomedullin |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
PT1214600E (en) * | 1999-09-10 | 2006-05-31 | Us Gov Health & Human Serv | DETERMINATION OF PROTEINS FROM LIGACAO TO ADRENOMEDULIN |
WO2003020746A1 (en) | 2001-08-30 | 2003-03-13 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins |
PT1941867E (en) | 2002-06-07 | 2012-02-16 | Dyax Corp | Modified kunitz domain polypeptide |
DE10316583A1 (en) * | 2003-04-10 | 2004-10-28 | B.R.A.H.M.S Aktiengesellschaft | Determination of a mid-regional proadrenomedullin partial peptide in biological fluids for diagnostic purposes, as well as immunoassays for carrying out such a determination |
WO2004097423A1 (en) | 2003-04-25 | 2004-11-11 | Genova Ltd. | Secreted polypeptide species reduced cardiovascular disorders |
US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
EP1800131A2 (en) | 2004-09-09 | 2007-06-27 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr) |
US8278262B2 (en) | 2004-09-21 | 2012-10-02 | Biontech Ag | Use of microproteins as tryptase inhibitors |
EP1731910A1 (en) * | 2005-06-07 | 2006-12-13 | F. Hoffmann-La Roche Ag | Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases |
DE102006060112A1 (en) | 2006-12-20 | 2008-06-26 | Brahms Aktiengesellschaft | Diagnosis and risk stratification using the new marker CT-proADM |
EP2231860B1 (en) | 2007-12-19 | 2011-10-05 | Affibody AB | Polypeptide derived from protein a and able to bind pdgf |
RU2650765C1 (en) | 2008-11-03 | 2018-04-17 | Молекьюлар Партнерс Аг | Binding proteins, inhibiting interaction of vegf-a receptor |
US9376477B2 (en) | 2009-08-27 | 2016-06-28 | Covagen Ag | IL-17 binding compounds and medical uses thereof |
WO2011073209A1 (en) | 2009-12-14 | 2011-06-23 | Scil Proteins Gmbh | Modified ubiquitin proteins having a specific binding activity for the extradomain b of fibronectin |
NZ603562A (en) | 2010-06-08 | 2014-07-25 | Pieris Ag | Tear lipocalin muteins binding il-4 r alpha |
NZ624873A (en) | 2011-11-16 | 2016-07-29 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition |
ES2751492T3 (en) | 2011-11-16 | 2020-03-31 | Adrenomed Ag | Anti-adrenomedullin antibody (ADM) or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for use in therapy of an acute disease or acute condition of a patient to stabilize circulation |
MY192113A (en) | 2011-11-16 | 2022-07-28 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment of anti-adm non-ig protein scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition |
PT2594588E (en) * | 2011-11-16 | 2014-08-28 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy |
PT2780371T (en) * | 2011-11-16 | 2019-01-30 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease |
WO2013072510A1 (en) | 2011-11-16 | 2013-05-23 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition |
CA2907467A1 (en) * | 2013-03-20 | 2014-09-25 | Sphingotec Gmbh | Adrenomedullin to guide therapy of blood pressure decline |
-
2018
- 2018-10-18 SG SG11202002268XA patent/SG11202002268XA/en unknown
- 2018-10-18 JP JP2020521927A patent/JP2021500548A/en active Pending
- 2018-10-18 CA CA3079112A patent/CA3079112A1/en active Pending
- 2018-10-18 AU AU2018350861A patent/AU2018350861A1/en not_active Abandoned
- 2018-10-18 US US16/756,903 patent/US20220268761A1/en not_active Abandoned
- 2018-10-18 MX MX2020004072A patent/MX2020004072A/en unknown
- 2018-10-18 BR BR112020005682-0A patent/BR112020005682A2/en unknown
- 2018-10-18 CN CN201880067951.7A patent/CN111480076A/en active Pending
- 2018-10-18 EP EP18785686.9A patent/EP3698134A1/en active Pending
- 2018-10-18 WO PCT/EP2018/078647 patent/WO2019077082A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3698134A1 (en) | 2020-08-26 |
CN111480076A (en) | 2020-07-31 |
AU2018350861A1 (en) | 2020-04-09 |
MX2020004072A (en) | 2020-07-28 |
RU2020115794A3 (en) | 2022-01-27 |
WO2019077082A1 (en) | 2019-04-25 |
BR112020005682A2 (en) | 2020-10-20 |
US20220268761A1 (en) | 2022-08-25 |
JP2021500548A (en) | 2021-01-07 |
RU2020115794A (en) | 2021-11-19 |
CA3079112A1 (en) | 2019-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202002268XA (en) | Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder | |
PT3618875T (en) | Combination therapy | |
IL272560A (en) | Combination therapy | |
GB201713914D0 (en) | Combination therapy | |
GB201710360D0 (en) | Patient monitoring | |
GB201713113D0 (en) | Combination therapy | |
GB201706260D0 (en) | Combination therapy | |
GB201706252D0 (en) | Combination therapy | |
GB201706249D0 (en) | Combination therapy | |
GB201706248D0 (en) | Combination therapy | |
GB201706247D0 (en) | Combination therapy | |
GB201706246D0 (en) | Combination therapy | |
GB201706244D0 (en) | Combination therapy | |
GB201706243D0 (en) | Combination therapy | |
GB201706242D0 (en) | Combination therapy | |
GB201706241D0 (en) | Combination therapy | |
GB201706251D0 (en) | Combination therapy | |
GB201706240D0 (en) | Combination therapy | |
GB201706239D0 (en) | Combination therapy | |
GB201706238D0 (en) | Combination therapy | |
GB201706237D0 (en) | Combination therapy | |
GB201706236D0 (en) | Combination therapy | |
GB201706261D0 (en) | Combination therapy | |
GB201706232D0 (en) | Combination therapy | |
GB201706235D0 (en) | Combination therapy |